|
|
Background: This study investigates the value of apolipoprotein A1 in assessing the occurrence and prognosis of cardiovascular events in peritoneal dialysis patients.
Methods: A retrospective analysis was conducted based on the clinical information of 80 end-stage renal disease patients who underwent peritoneal dialysis at Zhuji People's Hospital Zhejiang Province from January 2015 to December 2016. Based on the median value of apolipoprotein A1, patients were evenly distributed as either High Apolipoprotein A1 Group (H-ApoA1, > 1.145g/L, n = 40) or Low Apolipoprotein A1 Group (L-ApoA1, < 1.145g/L, n = 40).
Results: When compared with the H-ApoA1 group, the L-ApoA1 group patients were observed to have higher BMI, total Kt/V, hemoglobin, AKP, glycated hemoglobin, HOMA-IR, HDL levels, while simultaneously having lower total Ccr, triglycerides, total cholesterol, LDL, CRP levels (p < 0.05). Further analysis found that the all-cause mortality rate, cardiovascular death rate, and cardiovascular event rates were significantly higher in L-ApoA1 group patients than the H-ApoA1 group (p < 0.05); no statistical significance was found for mortality rates due to infection, abandon treatment, tumor, failure, gastrointestinal bleeding or undetermined reasons between the two groups (p > 0.05). In addition, the median all-cause mortality and median occurrence of cardiovascular events of L-ApoA1 group patients were observed to be shorter than the H-ApoA1 group (p < 0.05), and apolipoprotein A1 is a risk factor for all-cause mortality rate and cardiovascular occurrence end-point events (p < 0.05).
Conclusions: Peritoneal dialysis patients with a reduced level of apolipoprotein A1 have a poorer prognosis and more severe cardiovascular events.
DOI: 10.7754/Clin.Lab.2022.211211
|
